News brief­ing: FDA lifts a hold on Po­sei­da study; Deci­bel adopts 2-AAV ap­proach to hear­ing loss; As­traZeneca part­ners on com­bos, again

A lit­tle more than 2 months ago, shares of new­ly pub­lic Po­sei­da Ther­a­peu­tics $PSTX cratered af­ter the biotech re­port­ed that a pa­tient death had spurred the FDA to drop a full hold on its lead can­cer drug. This morn­ing we learned that reg­u­la­tors lift­ed the hold, but de­tails are sparse.

In a state­ment out ear­ly Mon­day, Po­sei­da said that reg­u­la­tors had lift­ed the hold on their Phase I study for their CAR-T P-PS­MA-101 in prostate can­cer. Here’s why:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.